EPH148 Insights From a French Postmarketing Authorization Early Access (MA EA) Mechanism: Projecting Clinical and Economic Benefits of Neoadjuvant Nivolumab–Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.1277
https://www.valueinhealthjournal.com/article/S1098-3015(25)03834-3/fulltext
Title :
EPH148 Insights From a French Postmarketing Authorization Early Access (MA EA) Mechanism: Projecting Clinical and Economic Benefits of Neoadjuvant Nivolumab–Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)03834-3&doi=10.1016/j.jval.2025.09.1277
First page :
Section Title :
Open access? :
No
Section Order :
10821